부산대학교 도서관

This article discusses the duration of treatment with cemiplimab, a type of immune checkpoint inhibitor, in patients with advanced cutaneous squamous cell carcinoma (cSCC) who have achieved a complete response (CR). The study collected data from 46 patients who received cemiplimab and found that the median duration of treatment was 11.2 months, with a median time to CR of 6.1 months. After achieving CR, the median treatment duration was 3.1 months. The study suggests that a treatment duration of at least 3 months after CR may be appropriate, but further research and long-term follow-up are needed to confirm these findings. The article also highlights the importance of avoiding overtreatment to minimize side effects and financial costs. [Extracted from the article]